Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.
The study will recruit 160 people aged 20 to 85, the companies said in a statement. They had earlier agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.